Covid19 vaccine coming much sooner than expected

China: Avigan effective in tackling coronavirus

the tests were conducted in the cities of Wuhan and Shenzhen and involved 240 patients and 80 patients respectively.

He said those who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive, while it took a median of 11 days for those without the drug.

The trial also found that X-ray photos confirmed improvements in lung conditions in about 91 percent of the patients who were given the medicine. The number stood at 62 percent for those without the drug.

The director said the drug is highly safe and its effect is obvious, and formally recommend the use of the medicine as a way to tackle the virus.

A Chinese firm that has licensed the drug from its Japanese developers got government approval last month to mass-produce the medication.

1 Like

Let’s hope!  

Nope will be awhile for the vaccine. They have to test it thoroughly against a meaningful sample to make sure its safe.

Go for it, nerds!

Dangerousdoug - Nope will be awhile for the vaccine. They have to test it thoroughly against a meaningful sample to make sure its safe.

NiteProwleR - 
Dangerousdoug - Nope will be awhile for the vaccine. They have to test it thoroughly against a meaningful sample to make sure its safe.

FUck gollum. The fellowship is the best of the series due to his stupid fake looking annoying ass not being in it. hes only referenced briefly. fellowship had the most memorable scenes and was the most ‘adventurey’.

That‘s not a vaccine. This is medicine that you take after you get it to help get rid of it.

1 Like
Dangerousdoug - Nope will be awhile for the vaccine. They have to test it thoroughly against a meaningful sample to make sure its safe.

This is one situation where I'm hoping Trump's belligerence and contempt for science works to everyone's benefit.  Fuck the protocol, bring us the cure or the zombie apocalypse.  Push it through Trump.  I'll mail in a vote for you this fall from Canada.

me lurk you long time -

That‘s not a vaccine. This is medicine that you take after you get it to help get rid of it.

True but access to rapid testing plus speculative treatment could help us all calm the fuck down and move on with life.

When might experimental drugs to treat Covid-19 be ready? A forecast

Existing antiviral medicines

Timeline:<span 400;"> Available now, but efficacy testing could take a month or more.

<span 400;">An existing, easy-to-produce medicine that proved effective at treating or preventing SARS-CoV-2 infection would provide the fastest relief for patients and doctors. The early hope is on hydroxychloroquine and chloroquine, and many hospitals, including the University of California, San Francisco, and the University of Washington, include them in their treatment guidelines. Some doctors are combining hydroxychloroquine with azithromycin, an antibiotic. Much of the published evidence comes from a very small French study and reports from China. Larger, more rigorous clinical trials are starting, but they will take time. Favipiravir, a flu drug shown in Japan, appeared beneficial in another small study. These medicines, especially the malaria drugs, which are being mass-produced, will be used by doctors on the front lines, but we will have to wait for evidence of whether they are benefitting patients and how much.


Timeline: <span 400;">First data could come in April

<span 400;">Remdesivir<span 400;">, an antiviral medicine that failed as an Ebola treatment, was initially developed to work against a different coronavirus. There’s some evidence that it benefits Covid-19 patients. Its maker, Gilead, has been working with researchers and governments around the world to get clinical trials up and running. The company has said to expect results in April. Six large studies are in progress, with the first, in severely ill patients in China, due to finish as early as April 3, according to a government website. A study in patients with milder disease will also finish in April, with two more due in May. In the meantime, Gilead has made the drug available to hundreds of patients on a compassionate use basis. However, it recently said that, due to overwhelming demand, it would <span 400;">suspend access<span 400;"> to the drug for all but pregnant women and children as it works to create a more systematic way of giving it out without interfering with clinical trials. This new system should be in place soon. Remdesivir must be given intravenously.


Convalescent plasma

Timeline: <span 400;">May see some use immediately, but research could take months

<span 400;">It’s an old idea that has proven effective in other epidemics: give patients who are sick <span 400;">blood plasma<span 400;"> from those who have recovered. It can work because the plasma contains antibodies against the virus, weaponizing the immune system of the sick patient.

<span 400;">One recent study <span 400;">from China<span 400;"> reported that of 10 patients given convalescent plasma, seven saw their viral loads become undetectable; it noted other improvements in their condition.

<span 400;">Takeda is developing a more refined version of this approach that uses more concentrated antibodies taken from blood. Julie Kim, the president of the company’s blood products division, said last Wednesday on a conference call with reporters organized by PhRMA, the trade group, that the product may be available in nine to 18 months.

Arthritis drugs

Timeline: <span 400;">Data could be available by summer; drugs available now

<span 400;">Drugs against autoimmune diseases like rheumatoid arthritis work by tamping down the immune system. This could, ironically, be useful against in Covid-19, because the SARS-CoV-2 virus can make the body overreact, causing what’s called a “cytokine storm,” damaging the body.

<span 400;">Actemra, one such drug made by Roche, is approved for treating the cytokine storm when it is caused by cancer treatments. An unpublished 21-patient study in China showed Actemra reduced fevers and need for supplemental oxygen. Two other firms, Regeneron and Sanofi, launched a study of their similar drug, Kevzara, in Covid-19 patients; the pair has said results on fevers and oxygen use could be available as early as April. Roche has begun its own study of Actemra in the U.S. Both Actemra and Kevzara are artificial antibodies that target a protein involved in the immune system called IL-6, and are given by injection.

1 Like

Artificial antibodies against the virus

Timeline: <span 400;">Potentially <span 400;">early fall

<span 400;">Many of the pharmaceutical industry’s best-sellers are what are called monoclonal antibodies, which are antibodies developed in mice and then made into drugs that can be injected into patients.

<span 400;">A manufactured antibody, or a mix of manufactured antibodies, might have a more consistent impact than using blood plasma, and it can be off-the-shelf. Regeneron, the Tarrytown, N.Y., biotech, had success developing a mixture of antibodies against Ebola; it is <span 400;">now selecting two to use against SARS-CoV-2<span 400;">, with the expectation that trials could start by early summer. If all goes well, it could be available by early fall for some uses, like treating extremely sick patients. Eli Lilly, working with a Vancouver startup called AbCellera, has said it hopes to start trials of a similar approach within four months. Vir Biotechnology and Biogen are following a similar path. Antibodies might also be used to prevent infection, but that could take longer to test in studies.

New antivirals

Timeline: <span 400;">2021 at the earliest

<span 400;">If existing antivirals cannot control SARS-CoV-2, brand new medicines may be needed. But this process is at square one, and even moving at full-speed could eat up months. Efforts are underway to search chemical libraries for medicines that could prove effective by the Bill and Melinda Gates Foundation and others. If they can find medicines that have gone through some previous testing, as remdesivir has, that could hasten the process.


Timeline:<span 400;"> Late 2021, possibly many years

<span 400;">There is one approach that could deliver a vaccine faster than others: It uses messenger RNA to make cells produce proteins that could lead to immunity. This approach has never been used in a widely available vaccine. The <span 400;">biotech Moderna is in the lead here<span 400;">, but others, such as BioNTech, working with Pfizer, are working on a similar approach.

<span 400;">It could take 18 months to be sure that approach works and is broadly safe. Even with increased manufacturing capacity, supply could be a problem. Other approaches are being developed in tandem, including one from Sanofi, now used for flu vaccines, that manufactures vaccines in insect cells. However, Moderna said in a filing with the SEC Monday that its vaccine might be available for some groups, including health care workers, as early as fall 2020.

<span 400;">“If you look across the many programs that have been launched, if you look at <span 400;">history, not all of those programs will be successful,” said Rajeev Venkayya, president of Takeda’s global vaccines unit, during <span 400;">a press conference<span 400;"> last week. “And I think that is something that I don’t think we’ve effectively communicated to the public. Just because we start a vaccine program doesn’t mean that we will definitely get a vaccine on the other end.”

<span 400;">The good news about having so many efforts in progress, he said, is it increases the chances that one will succeed.

A vaccine is far away. We're looking well into next year or even longer before one is released.

Good news when we do get a vaccine:

Coronavirus isn’t mutating quickly, suggesting a vaccine would offer lasting protection